The ongoing fluctuations in the dollar rate in Sudan have led to a deepening crisis in the medicine sector. As the country heavily relies on imported and locally manufactured medicines that depend on dollar-linked production inputs, price hikes have become a significant concern. The dollar rate has seen a considerable increase, reaching over 8700 Sudanese pounds for selling and approximately 8600 pounds for purchasing. This has resulted in a substantial surge in medicine prices, ranging from 60% to 65%, affecting crucial medications for chronic and life-threatening conditions.
The impact of the dollar rate fluctuations on Sudan's medicine sector has been substantial. Medicines for chronic diseases such as diabetes, hypertension, heart conditions, and mental health disorders, as well as children's medications, have been particularly affected. Industry sources have highlighted that the reliance on imported raw materials and dollar-linked production costs has made it challenging for companies to maintain stable prices. As a result, some companies have been forced to reduce imports or cease operations, leading to a shortage of essential medicines in the market.
The scarcity of medicines in Sudan has created an environment conducive to smuggling. As the legitimate market struggles to meet demand, smugglers have capitalized on the situation, importing medicines that often bypass quality control and regulatory measures. This poses significant risks to public health, as smuggled medicines may not meet the required standards for storage, transportation, and quality. Insulin, for example, requires refrigeration to maintain its efficacy, and improper handling can render it ineffective or even harmful.
The financing of medicine imports and distribution in Sudan has also been affected by the dollar rate fluctuations. Companies and pharmacies often rely on debt financing from suppliers, but the unpredictable exchange rates have increased the risk of losses. As a result, some businesses have had to limit their sales or cease financing, further exacerbating the medicine shortage. The situation has also led to concerns about the potential for companies to exit the market, reducing competition and further limiting access to essential medicines.
Industry experts have proposed potential solutions to address the crisis, including allocating dollars for medicine imports at a subsidized exchange rate. This approach could help stabilize medicine prices and ensure a consistent supply. However, it requires the government to provide a significant amount of foreign currency regularly. Another option is to liberalize medicine pricing, allowing companies to adjust prices in line with exchange rate fluctuations. While this could help companies maintain profitability, it may also lead to higher prices and reduced access to medicines for low-income households.
Amin Mekki, a member of Sudan's National Council for Medicines and Poisons, has warned that the ongoing dollar rate fluctuations and scarcity of foreign currency will continue to exacerbate the medicine crisis. He emphasized that the council is responsible for setting medicine prices and regulating the industry. Mekki pointed to the experience of the transitional government in 2021, which provided dollars for medicine imports through auctions, allowing companies to import essential medicines.
The situation in Sudan's medicine sector remains critical, with concerns about the impact of dollar rate fluctuations on medicine prices and availability. As the crisis deepens, there are fears that the smuggling of medicines will continue to grow, posing significant risks to public health. The National Council for Medicines and Poisons has emphasized the need for a stable and reliable supply of foreign currency to address the crisis and ensure that essential medicines remain accessible to the population.
Key points
- The fluctuations in the dollar rate have driven up medicine prices in Sudan by 60-65%.
- The scarcity of medicines has led to an increase in smuggling, posing risks to public health.
- Proposed solutions include allocating dollars for medicine imports at a subsidized rate or liberalizing medicine pricing.
